论文部分内容阅读
Background: Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication that follows solid organ transplantation or allogeneic hematopoietic stem cell transplantation (allo-HSCT).The managements of systemic PTLD, including EBV molecular monitoring to identify high-risk patients developing PTLD, diagnosis, preemptive therapy and treatments, have achieved certain consensus.